Inclusion Criteria:

          -  Participants with hepatic impairment.

          -  Participants eligible for Group 4 should be in good health.

          -  Participants eligible for Groups 1 through 3 may have medical findings consistent with
             their degree of hepatic dysfunction.

          -  Participants with abnormal findings considered not clinically significant by the
             investigator are eligible.

          -  Body mass index within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening.

          -  Willingness to avoid pregnancy or fathering children.

        Exclusion Criteria:

          -  Evidence of rapidly deteriorating hepatic function.

          -  Participants with serum calcium and phosphorus levels over the upper limits of the
             institutional normal ranges.

          -  History or current diagnosis of uncontrolled or significant cardiac disease indicating
             significant risk of safety for participation in the study, including any of the
             following:

          -  Participants who have a current, functioning organ transplant or have a scheduled
             organ transplant in the next 6 weeks from check-in.

          -  History of malignancy within 5 years of screening, with the exception of cured basal
             cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or
             Gleason 6 prostate cancer.

          -  History of clinically significant gastrointestinal disease or surgery (cholecystectomy
             and appendectomy are allowed) that could impact the absorption of study drug.

          -  Participants with severe ascites or an encephalopathy ≥ Grade 2.

          -  Any major surgery within 4 weeks of screening.

          -  Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for
             plasma only).

          -  Blood transfusion within 4 weeks of check-in. Current or recent history (within 30
             days before screening) of a clinically significant bacterial, fungal, parasitic, or
             mycobacterial infection, or currently receiving systemic antibiotics. Current
             clinically significant viral infection at screening or check-in.

          -  Positive serology for hepatitis B virus (eg, hepatitis B surface antigen) or human
             immunodeficiency virus. Participants whose results are compatible with immunity due to
             infection or prior immunization for hepatitis B may be included at the discretion of
             the investigator.

          -  History of alcoholism within 3 months of screening.

          -  Positive breath test for ethanol or positive urine screen for drugs of abuse that is
             not otherwise explained by permitted concomitant medications.

          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of
             study drug administration with another investigational medication or current
             enrollment in another investigational drug protocol.

          -  Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of
             study drug administration with strong or moderate inducer or potent inhibitor of
             CYP3A4.

          -  Receipt of live (including attenuated) vaccines or anticipation of need for such a
             vaccine during the study. (Note: Non-live or inactivated vaccines allowed up to 2
             weeks before first dose administration.)

          -  Known hypersensitivity or severe reaction to parsaclisib or excipients of parsaclisib.

          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed
             clinically relevant by the investigator. Inability to be venipunctured or tolerate
             venous access.

          -  Participants eligible for Group 4 who have a history or presence of liver disease or
             liver injury as indicated by an abnormal clinically significant liver function profile
             at screening or check-in.

          -  Participants eligible for Group 4 who have a positive test for hepatitis C virus.

          -  Participants eligible for Group 4 who used tobacco- or nicotine-containing products
             within 6 months of screening.

          -  Women who are pregnant or breastfeeding